17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

17(R)-RvD1 possesses anti-hyperuricemic and anti-inflammatory effects, and the underlying mechanism for ameliorating hepatic injury in hyperuricemia is the inhibition of cell pyroptosis via downregulating the NF-κB signaling pathway. 17(R)-RvD1 could serve as an ideal candidate drug and increase options for the treatment of hyperuricemia.